FDA clears Novo Nordisk's insulin injection pen for children

NovoPen Echo--Courtesy of Novo Nordisk

Novo Nordisk ($NVO) landed FDA clearance for its insulin injection pen that allows for fine dose adjustments and includes a memory function to record the time since a patient's last injection. The company developed its NovoPen Echo specifically for children, incorporating simple functionality with a sleek, colorful design. The U.S. agency's 510(k) clearance will help the Echo reach Novo's intended launch goal of early 2014--the device is already available in Europe, Canada and Israel. Release